TAPP1 Inhibitors
TAPP1 inhibitors constitute a class of chemical compounds designed to target and modulate the activity of the TAPP1 protein, also known as ADP-ribosylation factor GTPase-activating protein 1 (ARAP1). TAPP1 is a multifunctional protein that is involved in various cellular processes, particularly those related to cell signaling, membrane dynamics, and cytoskeletal organization. TAPP1 is known to interact with several important signaling molecules, including phosphoinositides, GTPases, and adaptor proteins. Inhibitors of TAPP1 are developed to interfere with its interactions or functions, affecting signaling pathways, membrane dynamics, or other cellular processes regulated by this protein.
The mechanisms by which TAPP1 inhibitors function can vary based on their chemical structures and binding properties. Some inhibitors may directly interact with TAPP1, preventing its association with specific binding partners or disrupting its ability to interact with phosphoinositides or GTPases. Others may modulate the conformation or stability of TAPP1, affecting its ability to influence cellular processes such as membrane trafficking or cytoskeletal dynamics. By inhibiting TAPP1, these compounds impact cellular signaling events, membrane organization, or other processes associated with this protein. Ongoing research in this field aims to elucidate the precise mechanisms and downstream effects of TAPP1 inhibition, contributing to our understanding of its role in cellular biology and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that may lead to reduced TAPP1 expression by disrupting upstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor known to affect the PI3K/AKT pathway and could thus potentially influence TAPP1 expression. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
A PI3K inhibitor that could disrupt downstream signaling pathways, potentially leading to the reduced expression of TAPP1. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
A compound that inhibits PI3K and mTOR, which may affect signaling pathways involved in TAPP1 expression. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
An AKT inhibitor that could potentially downregulate TAPP1 expression by inhibiting AKT activity. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
An alkylphospholipid that inhibits AKT activation, potentially affecting TAPP1 expression indirectly. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
An allosteric inhibitor of AKT that may downregulate the expression of proteins controlled by the AKT pathway, possibly including TAPP1. | ||||||
AZD6482 | 1173900-33-8 | sc-364422 sc-364422A | 5 mg 10 mg | $275.00 $390.00 | 1 | |
A PI3Kβ inhibitor that could affect TAPP1 expression by specifically targeting the beta isoform of PI3K. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Specifically inhibits PI3Kδ, potentially affecting the expression of TAPP1 through altered lymphocyte function. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
A dual PI3K/mTOR inhibitor that might impact TAPP1 expression by targeting both PI3K and mTOR pathways. | ||||||